162694-63-5

Basic information

• Product Name: MELAGATRAN
• Synonyms: Glycine, N-[2-[2-[[[[4-(aminoiminomethyl)phenyl]methyl]amino]carbonyl]-1-azetidinyl]-1-cyclohexyl-2-oxoethyl]-
• CAS NO: 162694-63-5
• Molecular Formula: C22H31N5O4
• Molecular Weight: 429.51
• Mol File: 162694-63-5.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: MELAGATRAN(CAS DataBase Reference)
• NIST Chemistry Reference: MELAGATRAN(162694-63-5)
• EPA Substance Registry System: MELAGATRAN(162694-63-5)

Safety Data

• Hazardous Substances Data: 162694-63-5(Hazardous Substances Data)

Upstream product

• 192939-72-3 N-hydroxymelagatran 
• 217313-86-5 tert-butyl((4-((((benzyloxy)carbonyl)amino)(imino)methyl) benzyl)(tert-butoxycarbonyl)amino)methanoate 
• 162696-14-2 benzyl ((4-(((tert-butoxycarbonyl)amino)methyl)phenyl)(imino)methyl)carbamate 
• 510772-07-3 4-di-tert-butoxycarbonylaminomethyl-N-hydroxy-benzamidine 
• 217313-79-6 4-(aminomethyl)benzene-1-carboximidamide dihydrochloride 
• 172348-74-2 tert-butyl ((tert-butoxycarbonyl)(4-cyanobenzyl)amino)-methanoate 
• 217313-81-0 4-(tert-Butoxycarbonylamino-methyl)-thiobenzimidic acid methyl ester 
• 217313-80-9 (4-thiocarbamoyl-benzyl)-carbamic acid tert-butyl ester 
• 162696-15-3 N-Boc-4-aminomethyl benzamidine 
• 162698-08-0 4-amidinobenzyl azide 
• 17201-43-3 4-cyanobenzyl bromide 
• 66389-80-8 tert-butyl N-[(4-cyanophenyl)methyl]carbamate 
• 51077-14-6 (S)-1-(t-butoxycarbonyl)azetidine-2-carboxylic acid 
• 70491-05-3 (2R)-[(tert-butoxycarbonyl)-amino](cyclohexyl)ethanoic acid 

Relevant articles and documents

The fourth molybdenum containing enzyme mARC: Cloning and involvement in the activation of N-hydroxylated prodrugs

The recently discovered mammalian molybdoprotein mARC1 is capable of reducing N-hydroxylated compounds. Upon reconstitution with cytochrome b 5 and b5 reductase, benzamidoxime, pentamidine, and diminazene amidoximes, N-hydroxymelagatran, guanoxabenz, and N-hydroxydebrisoquine are efficiently reduced. These substances are amidoxime/N-hydroxyguanidine prodrugs, leading to improved bioavailability compared to the active amidines/guanidines. Thus, the recombinant enzyme allows prediction about in vivo reduction of N-hydroxylated prodrugs. Furthermore, the prodrug principle is not dependent on cytochrome P450 enzymes.